Trexquant Investment LP Has $5.44 Million Stock Holdings in Wave Life Sciences Ltd. (NASDAQ:WVE)

Trexquant Investment LP raised its stake in shares of Wave Life Sciences Ltd. (NASDAQ:WVE) by 52.1% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 439,352 shares of the company’s stock after buying an additional 150,538 shares during the period. Trexquant Investment LP owned about 0.29% of Wave Life Sciences worth $5,435,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of the stock. Loomis Sayles & Co. L P purchased a new position in Wave Life Sciences in the fourth quarter valued at about $20,545,000. FMR LLC grew its stake in shares of Wave Life Sciences by 174.5% in the 3rd quarter. FMR LLC now owns 1,540,190 shares of the company’s stock valued at $12,630,000 after buying an additional 979,110 shares in the last quarter. Charles Schwab Investment Management Inc. increased its holdings in Wave Life Sciences by 209.1% in the third quarter. Charles Schwab Investment Management Inc. now owns 844,617 shares of the company’s stock worth $6,926,000 after buying an additional 571,345 shares during the last quarter. Vanguard Group Inc. raised its position in Wave Life Sciences by 10.2% during the fourth quarter. Vanguard Group Inc. now owns 3,182,512 shares of the company’s stock valued at $39,368,000 after acquiring an additional 294,956 shares in the last quarter. Finally, Geode Capital Management LLC raised its position in Wave Life Sciences by 14.3% during the third quarter. Geode Capital Management LLC now owns 2,269,664 shares of the company’s stock valued at $18,615,000 after acquiring an additional 283,419 shares in the last quarter. 89.73% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Wave Life Sciences

In other news, Director Christian O. Henry sold 10,500 shares of the business’s stock in a transaction that occurred on Thursday, March 20th. The stock was sold at an average price of $9.77, for a total transaction of $102,585.00. Following the sale, the director now directly owns 16,115 shares in the company, valued at approximately $157,443.55. The trade was a 39.45 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Paul Bolno sold 169,025 shares of the firm’s stock in a transaction on Friday, March 7th. The stock was sold at an average price of $9.57, for a total value of $1,617,569.25. Following the completion of the transaction, the chief executive officer now directly owns 338,351 shares of the company’s stock, valued at approximately $3,238,019.07. This trade represents a 33.31 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 29.10% of the company’s stock.

Wave Life Sciences Stock Down 9.2 %

Shares of NASDAQ:WVE opened at $6.03 on Friday. The business has a 50 day moving average price of $10.30 and a 200 day moving average price of $11.69. The company has a market cap of $925.52 million, a price-to-earnings ratio of -5.43 and a beta of -0.93. Wave Life Sciences Ltd. has a twelve month low of $4.25 and a twelve month high of $16.74.

Wave Life Sciences (NASDAQ:WVE) last announced its quarterly earnings data on Tuesday, March 4th. The company reported $0.17 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.17) by $0.34. The business had revenue of $83.75 million for the quarter, compared to the consensus estimate of $25.60 million. Wave Life Sciences had a negative net margin of 66.50% and a negative return on equity of 280.57%. Analysts anticipate that Wave Life Sciences Ltd. will post -1.14 EPS for the current year.

Analysts Set New Price Targets

Several research analysts have recently commented on WVE shares. StockNews.com upgraded shares of Wave Life Sciences from a “sell” rating to a “hold” rating in a research note on Saturday, March 8th. HC Wainwright restated a “buy” rating and set a $22.00 target price on shares of Wave Life Sciences in a report on Wednesday, March 26th. Finally, Jefferies Financial Group began coverage on Wave Life Sciences in a research note on Tuesday, February 25th. They set a “buy” rating and a $26.00 price target for the company. Two research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, Wave Life Sciences presently has a consensus rating of “Moderate Buy” and a consensus target price of $22.60.

Wave Life Sciences Profile

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders.